Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.

Wayfair (W)

Consensus Price Target: $105.41 (42.5% implied return)

Founded in 2002 by Niraj Shah, Wayfair (NYSE: W) is a leading online retailer of mass-market home goods in the US, UK, Canada, and Germany.

Why Are We Wary of W?

1. Intense competition is diverting traffic from its platform as its active customers fell by 2.3% annually
2. Estimated sales growth of 5.3% for the next 12 months is soft and implies weaker demand
3. Bad unit economics and steep infrastructure costs are reflected in its low gross margin of 30.2%

Wayfair is trading at $73.99 per share, or 14.7x forward EV/EBITDA. If you’re considering W for your portfolio, see our FREE research report to learn more.

Amplitude (AMPL)

Consensus Price Target: $12.70 (71.5% implied return)

Born from the realization that companies were flying blind when it came to understanding user behavior in their digital products, Amplitude (NASDAQ: AMPL) provides a digital analytics platform that helps businesses understand how people use their digital products to improve user experiences and drive revenue growth.

Why Does AMPL Fall Short?

1. Struggled to drive increased usage of its software, demonstrated by its subpar 102% net revenue retention rate
2. Persistent operating margin losses suggest the business manages its expenses poorly
3. Poor free cash flow margin of 6.8% for the last year limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends

Amplitude’s stock price of $7.41 implies a valuation ratio of 2.6x forward price-to-sales. Check out our free in-depth research report to learn more about why AMPL doesn’t pass our bar.

Organon (OGN)

Consensus Price Target: $9 (42% implied return)

Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE: OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines.

Why Does OGN Give Us Pause?

1. Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last five years
2. Earnings per share have dipped by 12.8% annually over the past four years, which is concerning because stock prices follow EPS over the long term
3. Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 22.6 percentage points

At $6.34 per share, Organon trades at 1.8x forward P/E. Dive into our free research report to see why there are better opportunities than OGN.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.